RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Nathaniel E. Eraikhuemen to Oligonucleotides, Antisense

Back to Details
This is a "connection" page, showing publications Nathaniel E. Eraikhuemen has written about Oligonucleotides, Antisense.
Nathaniel E. Eraikhuemen
Connection Strength
0.196
Oligonucleotides, Antisense
  1. Eraikhuemen N, Lazaridis D, Dutton MT. Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. Am J Cardiovasc Drugs. 2021 May; 21(3):255-265.
    View in: PubMed
    Score: 0.196
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support